J A M Weijers,N J van Ruitenbeek,A C H van Engen-van Grunsven et al.
J A M Weijers et al.
Background: Salivary gland cancer (SGC) is a rare cancer comprising over 20 subtypes. Although its molecular landscape is increasingly characterised, real-world data on molecular-matched therapies (MMTs) remain limited, a...
Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors [0.03%]
J Ros,M C de Grandis,V Navarro et al.
J Ros et al.
Background: The optimal duration of immune checkpoint inhibitor (ICI) treatment in patients with metastatic colorectal cancer (mCRC) with microsatellite instability/mismatch repair deficiency (MSI/dMMR) remains undefined....
Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
眼黑色素瘤：诊断、治疗和随访的ESMO-EURACAN临床实践指南
S Piperno-Neumann,M Angi,P A Ascierto et al.
S Piperno-Neumann et al.
•This ESMO CPG provides key recommendations and algorithms for diagnosis, staging, treatment and follow-up of UM.•This ESMO CPG focuses solely on UM; refer to the ESMO CPG on Cutaneous Melanoma for other types.•ESMO-MCBS scores are given...
Practice Guideline
ESMO open. 2026 Apr;11(4):106888. DOI:10.1016/j.esmoop.2026.106888 2026
Response to letter re: "Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study" [0.03%]
关于“头颈部癌症复发和生存的实时多模态预测模型：一项国际多中心研究”的来信回复
H A Jung,R Merkin,A L Feng et al.
H A Jung et al.
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study [0.03%]
全球真实世界证据研究中的免疫检查点抑制剂再输注治疗转移性透明细胞肾细胞癌的疗效：结果分析
A Cigliola,B A Maiorano,F Rossari et al.
A Cigliola et al.
Background: Immune-checkpoint inhibitors (ICIs), with or without tyrosine kinase inhibitors (TKIs), represent the backbone first-line treatment of patients (pts) with metastatic clear-cell renal cell carcinoma (mccRCC). A...
First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies [0.03%]
ATOR-1015（CTLA-4×OX40双特异性抗体）治疗晚期实体瘤的首次人体研究
V Ekström-Rydén,A Carneiro,J Yachnin et al.
V Ekström-Rydén et al.
Background: Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), was the first approved checkpoint inhibitor; however, its use is hampered by treatment-related adverse events (TR...
Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab [0.03%]
在伊匹单抗和纳武利尤单抗治疗的伴有或不伴有肉瘤样/横纹肌样肾细胞癌患者中，隔室特异性免疫和肿瘤标志物与临床结果相关性研究
N Savion-Gaiger,O Perales,D G Su et al.
N Savion-Gaiger et al.
Background: Immune checkpoint inhibition with ipilimumab and nivolumab prolongs survival in renal cell carcinoma (RCC). Tumors with sarcomatoid and/or rhabdoid features are considered responsive to immune checkpoint inhib...
Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE [0.03%]
德瓦卢单抗联合卡铂/紫杉醇用于不适合顺铂化疗的复发和/或转移性头颈部鳞癌患者的一线治疗：FRAIL-IMMUNE多中心前瞻性研究结果
J Fayette,C Cropet,C Toullec et al.
J Fayette et al.
Background: Pembrolizumab, combined with platinum-5-FU or as a monotherapy, is the standard treatment of patients with recurrent and/or metastatic (R/M) head and neck squamous-cell carcinoma (HNSCC). This treatment is use...
Clinical Trial
ESMO open. 2026 Apr;11(4):106946. DOI:10.1016/j.esmoop.2026.106946 2026
Patterns and quality of therapeutic care for glioma: a population-based study in Belgium between 2016 and 2019 [0.03%]
2016年至2019年比利时胶质瘤治疗模式及质量的群体研究
D Vanhauwaert,K Vanschoenbeek,G Silvermit et al.
D Vanhauwaert et al.
Background: The study aimed to evaluate the patterns and quality of therapeutic care and pathological diagnosis for glioma patients by calculating process indicators across Belgian hospitals. ...
New prognostic and predictive scoring systems for colorectal cancer liver metastases [0.03%]
结直肠癌肝转移的新型预后及预测评分系统
F Salvà,S Pérez Fernandez,C Dopazo et al.
F Salvà et al.
Colorectal cancer liver metastases (CRLM) remain a major therapeutic challenge, shaped by marked biological heterogeneity and unpredictable clinical outcomes. While classical Clinical Risk Scores (CRS) continue to inform surgical decision m...